Indaptus Therapeutics, Inc.
INDP
$2.16
$0.168.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -50.61% | 29.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -40.57% | -2.53% | |||
| Operating Income | 40.57% | 2.53% | |||
| Income Before Tax | 43.10% | -15.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 43.10% | -15.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 43.10% | -15.37% | |||
| EBIT | 40.57% | 2.53% | |||
| EBITDA | 40.58% | 2.53% | |||
| EPS Basic | 67.19% | -1.07% | |||
| Normalized Basic EPS | 67.19% | -1.07% | |||
| EPS Diluted | 67.19% | -1.07% | |||
| Normalized Diluted EPS | 67.19% | -1.07% | |||
| Average Basic Shares Outstanding | 73.42% | 14.14% | |||
| Average Diluted Shares Outstanding | 73.42% | 14.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||